AUSTIN, TX – GX Sciences™ is now offering quick and easy blood analysis testing, known as Microsampling, through a unique Mitra^® device, by Neoteryx. Blood Microsampling is an efficient and more simplified method of traditional blood sampling that allows patients to draw their own blood and securely mail the samples to the GX Sciences™ lab for analysis. Providers are now able to purchase Microsampling kits for their patients directly from the GX Sciences™ website.

Blood sampling has been a fundamental diagnostic tool for years, with the vast majority of all medical decisions being guided by diagnostic test results that include blood sample assessments. Blood sampling is not always convenient, with a large portion of the world's population being located in areas with limited or no quick access to medical facilities. However now, reduced blood sample sizes are gaining value and popularity where blood analysis testing is needed. Microsampling with GX Sciences™ is making blood analysis testing easier and more convenient for everyone.

Topics: Press Release, Microsampling in Action

Dried blood samples can replace urine and hair monitoring for measuring more specific distinctions in alcohol consumption.

Topics: Press Release

With significant worldwide growth in demand for microsampling technology, Neoteryx is opening new offices! We're expanding our European operations to better meet the needs of both new and existing customers for Mitra^® devices and better share all the capabilities that come with them.

Topics: Clinical Diagnostics, Pediatrics, Alternative to Venipuncture, Patient-Centered Medicine, Remote Patient Monitoring

At-home blood sampling streamlines the process of therapeutic drug monitoring and creates comfort and emotional safety for children

Topics: Press Release, Pediatrics, Microsampling in Action

 At-home blood sampling provides convenience and cost savings to patients.

TORRANCE, California (August 16, 2018) – Neoteryx LLC, inventor of Volumetric Absorptive Microsampling (VAMS™) technology, has signed a research agreement with Cedars-Sinai in Los Angeles to initiate a study to find and measure new biomarkers in blood that potentially may predict treatment effectiveness and relapse in patients with inflammatory bowel disease (IBD) – a chronic and recurring immune response and inflammation of the gastrointestinal tract.

Topics: Clinical Diagnostics, Press Release, Patient-Centered Medicine, Remote Patient Monitoring